Capricor Therapeutics (CAPR), Tuesday announced positive 3-year results from the ongoing HOPE-2 open-label, randomized, double-blind, placebo-controlled extension study with CAP-1002 for the treatment of Duchenne muscular dystrophy.
The biotechnology company said the CAP-1002 treatment has shown consistently well-tolerated safety profile throughout the study. The study observed a statistically significant reduction in Performance of the Upper Limb or PUL decline as well as stabilization in Left Ventricular Ejection Fraction or LVEF in CAP-1002 treated patients suggesting sustained disease attenuation.
The Company plans to present these results at the Parent Project Muscular Dystrophy 30th Annual Conference. The results from the Phase 3 HOPE-3 pivotal trial will be released in the fourth quarter of 2024.
Duchenne muscular dystrophy is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart and respiratory muscles with mortality at a median age of approximately 30 years.
Currently, shares are at $5.83, up 3.37 percent from the previous close of $5.64 on a volume of 42596.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.